Wykoff Charles C., Abreu Francis, Adamis Anthony P., Basu Karen, Eichenbaum David A., Haskova Zdenka, . . . Kollaborációs szervezet: YOSEMITE and RHINE Investigators. (2022). Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): Two randomised, double-masked, phase 3 trials.
Chicago Style (17th ed.) CitationWykoff Charles C., et al. Efficacy, Durability, and Safety of Intravitreal Faricimab with Extended Dosing Up to Every 16 Weeks in Patients with Diabetic Macular Oedema (YOSEMITE and RHINE): Two Randomised, Double-masked, Phase 3 Trials. 2022.
MLA idézésWykoff Charles C., et al. Efficacy, Durability, and Safety of Intravitreal Faricimab with Extended Dosing Up to Every 16 Weeks in Patients with Diabetic Macular Oedema (YOSEMITE and RHINE): Two Randomised, Double-masked, Phase 3 Trials. 2022.